Limitations, agreements, and source contact

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas · Source last updated 2026-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

ynieto@mdanderson.org

organization

UT MD Anderson Cancer Center

phone

713-792-8750

title

Yago Nieto, MD, PhD

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice